Brief: Alpine Immune Sciences And Horizon Therapeutics PLC Announce Exclusive License And Collaboration Deal

Alpine Immune Sciences

16/12/2021 14:41

Dec 16 (Reuters) - Horizon Therapeutics PLC  HZNP.O :
    * ALPINE IMMUNE SCIENCES AND HORIZON THERAPEUTICS PLC
ANNOUNCE
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT TO DEVELOP NOVEL
PROTEIN-BASED THERAPIES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
    * HORIZON THERAPEUTICS PLC - HORIZON WILL HAVE EXCLUSIVE
RIGHTS TO
DEVELOP AND COMMERCIALIZE UP TO FOUR PRECLINICAL CANDIDATES
    * HORIZON THERAPEUTICS PLC - HORIZON WILL MAKE $40 MILLION
PAYMENT
AT CLOSING, CONSISTING OF A $25 MILLION UPFRONT CASH PAYMENT AND
A $15 MILLION EQUITY INVESTMENT
    * HORIZON THERAPEUTICS PLC - ALPINE ELIGIBLE TO RECEIVE
ADDITIONAL
PAYMENTS OF UP TO $381 MILLION PER PROGRAM, OR APPROXIMATELY
$1.52 BILLION IN TOTAL
    * HORIZON THERAPEUTICS PLC - AGREEMENT COMBINES ALPINE'S
DISCOVERY
PLATFORM AND EXPERTISE WITH CO'S DRUG DEVELOPMENT AND
COMMERCIALIZATION CAPABILITIES

Source text for Eikon:  ID:nBwbgxgDxa 
Further company coverage:  HZNP.O 

 ((Reuters.Briefs@thomsonreuters.com;))